Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Abingworth LLP. (9/16/16). "Press Release: GammaDelta Therapeutics Raises Seed Funding from Abingworth".

Region Region London, Greater London
  Country United Kingdom (GB)
Organisations Organisation Abingworth LLP
  Group Abingworth (Group)
  Organisation 2 GammaDelta Therapeutics Ltd.
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 venture capital
Index term Index term GammaDelta Therapeutics–Abingworth: investment, 201609 seed funding from Abingworth
Persons Person Haines, Timothy (Tim) (Abingworth 201507– Managing Partner joined 2005 before Astex CEO)
  Person 2 Owen, Mike (Kymab 201007 CSO before GSK 200612 SVP Biopharmaceuticals CEDD)
     


Abingworth, the international investment group dedicated to life sciences, today announced that it has seeded GammaDelta Therapeutics Ltd, a new immunotherapy company. GammaDelta Therapeutics also received support from three organisations, Cancer Research Technology (CRT), King’s College London and the Francis Crick Institute. The company is being incubated at Abingworth’s London office.

GammaDelta Therapeutics has been founded on pioneering research by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute, funded in part by Cancer Research UK, into gamma delta (?d) T cells. These are a unique and conserved population of lymphocytes that contribute to many types of immune responses and immunopathologies. The new company is focused on exploiting this work to develop improved immunotherapies for cancer and potentially other diseases.

Peter Goodfellow, an advisor to Abingworth and formerly Senior Vice President for Discovery Research at GlaxoSmithKline, is Chairman of the board, which also includes, Prof. Hayday; Raj Mehta of CRT; Stephen Parker, Institutes Director; Mike Owen, formerly Senior Vice President for Biopharmaceuticals Research at GlaxoSmithKline; and Tim Haines, Managing Partner of Abingworth.

Raj Mehta, Founder and Interim CEO, said: “We are delighted to have attracted the support of Abingworth to the founding and development of GammaDelta Therapeutics and will use the proceeds to help us advance our innovative programmes into the clinic.”

“GammaDelta’s technology is differentiated from other approaches to immunotherapy being pursued and has the potential to make a significant impact on the treatment of cancer,” said Abingworth’s Tim Haines. “We look forward to working with the team to advance the discovery and development of novel therapeutic candidates based on this exciting approach.”


About GammaDelta Therapeutics

Founded in 2016, GammaDelta Therapeutics is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident ?d T cells for effective immunotherapy.

   
Record changed: 2016-09-20

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Abingworth (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px




» top